Midi Health LegitScript and Accreditation Status: Is Midi Health Legit?

What Is Midi Health and Who Does It Serve?

Midi Health is a telehealth company founded in 2021 that focuses specifically on women aged 35 and older experiencing perimenopause or menopause. Its clinical model pairs patients with nurse practitioners or physicians for video visits, follow-up messaging, and ongoing hormone therapy management.

The Clinical Scope

The platform offers evaluation and management of hot flashes, sleep disruption, mood changes, vaginal dryness, and related symptoms. Clinicians can prescribe FDA-approved hormone replacement therapy (HRT), including estradiol patches, oral progesterone (micronized progesterone, branded as Prometrium), and low-dose vaginal estrogens. Compounded bioidentical hormone preparations are also available in some cases, though the FDA has noted repeatedly that custom-compounded hormones lack the same safety and efficacy data as approved drug products. The FDA's guidance on compounded hormone therapy makes this distinction explicit.

Who Can Access the Platform

Midi Health operates in most U.S. States. Patients schedule online, complete an intake questionnaire, and connect with a clinician within days rather than weeks. The billing model accepts commercial insurance through in-network contracts with Aetna, Cigna, UnitedHealthcare, and several Blue Cross Blue Shield plans. Cash-pay pricing is available for patients without covered plans.

LegitScript Certification: Does Midi Health Have It?

Midi Health does not currently hold LegitScript certification as of July 2025. That finding matters because LegitScript is the most widely recognized third-party verification system for online pharmacies, telehealth prescribers, and health websites. Google, Meta, and the major ad networks require LegitScript certification before allowing pharmaceutical advertising, which means Midi Health cannot run direct drug-related paid ads on those platforms without it.

What LegitScript Certification Actually Means

LegitScript reviews an online pharmacy or telehealth operator against four criteria: state pharmacy licensure, prescriber legitimacy, compliance with applicable laws, and advertising accuracy. A "certified" status signals the operator has passed that audit. "Not certified" does not automatically mean illegal or unsafe. It means the platform has not submitted to or passed that independent audit process. LegitScript maintains a public search tool at legitscript.com where anyone can check status by website URL. A search of midi.health returns no active certification as of this writing.

Why the Absence Matters for Patients

Telehealth operators prescribing hormones, particularly compounded preparations, occupy a regulatory gray area that LegitScript certification helps clarify. Without it, patients cannot rely on that third-party signal to assess compliance. They must instead look at state medical board records, DEA registration status for any clinician prescribing controlled substances, and the BBB profile. None of those checks replace LegitScript, but together they give a reasonable picture.

The HealthRX editorial team developed the following four-point legitimacy check for any telehealth brand without LegitScript certification: (1) confirm the prescribing clinician's state license is active via the relevant state medical or nursing board; (2) check for DEA registration if controlled substances are involved; (3) review the platform's FDA adverse event or warning letter history at fda.gov; and (4) search the platform domain on the LegitScript monitor tool for a "rogue" or "unapproved" flag, which Midi Health does not currently carry.

BBB Profile and Patient Complaints

The Better Business Bureau does not currently accredit Midi Health. BBB accreditation is voluntary and fee-based, so its absence is not a red flag on its own. The relevant question is the complaint history.

Complaint Volume and Themes

As of this review, Midi Health has a limited number of filed BBB complaints, mostly in the single digits. The themes that appear in those complaints include billing disputes (charges after cancellation), difficulty reaching customer support, and delays in prescription processing. No complaints in the public BBB record allege that a clinician practiced without a license or prescribed in an unsafe manner.

Patient Review Patterns Elsewhere

On third-party review aggregators, Midi Health tends to score in the 4.0 to 4.5 out of 5 range, with high marks for clinician knowledge and low marks for administrative responsiveness. The pattern of billing and scheduling complaints mirrors what surfaces for most telehealth platforms that scale quickly. The Endocrine Society's 2023 clinical practice guideline on menopause hormone therapy, which states that "menopausal hormone therapy remains the most effective treatment for vasomotor symptoms," is consistent with what Midi Health's clinical team delivers. That alignment with mainstream guideline care is a positive signal for clinical quality, even if operational execution has drawn criticism. [1]

Prescriber Licensing and State Regulatory Standing

Telehealth legitimacy at the state level turns on whether the prescribing clinician holds an active, unrestricted license in the state where the patient is located. Midi Health employs primarily nurse practitioners (NPs) who hold advanced practice registered nurse (APRN) licenses, some with full-practice authority and others practicing under a collaborative agreement with a supervising physician.

How to Verify a Midi Health Clinician's License

Each U.S. State maintains a public license verification database. The National Practitioner Data Bank (NPDB) is a federal resource that records adverse actions against clinicians, though public queries are limited. The NPDB is accessible here. Patients can also search individual state nursing boards or the Federation of State Medical Boards at fsmb.org. Midi Health states on its website that all clinicians are state-licensed, but patients should run their own verification before a first visit.

Full-Practice Authority and Prescribing Scope

As of 2025, 27 states plus Washington D.C. Grant full-practice authority to NPs, meaning they can evaluate, diagnose, and prescribe without a supervising physician. The American Association of Nurse Practitioners tracks this map. In states without full-practice authority, Midi Health's NPs must have a collaborative agreement in place. Whether those agreements are active and valid is something the platform manages internally. Patients in states with restricted NP practice should ask directly whether their assigned clinician operates under a current collaboration agreement.

FDA-Approved vs. Compounded Hormones at Midi Health

This distinction carries real clinical and regulatory weight. FDA-approved hormone products, estradiol patches like Climara or Vivelle-Dot, oral micronized progesterone (Prometrium 100 mg or 200 mg), and vaginal estradiol products like Vagifem, have passed the FDA's review for safety, efficacy, and manufacturing quality. The FDA's approved drug database lists every approved product.

The Compounding Question

Midi Health, like many menopause-focused telehealth platforms, also offers access to compounded bioidentical hormones (cBHT). These are custom preparations made at compounding pharmacies that are not FDA-approved. The FDA has issued multiple guidance documents stating that compounded hormones are not equivalent to approved drugs and that the safety database for cBHT is substantially thinner than for conventional HRT. The FDA's position on cBHT is summarized here.

The North American Menopause Society (NAMS) 2022 position statement on hormone therapy states that "compounded hormone therapy is not recommended as first-line therapy" and that patients choosing compounded options "should be informed of the lack of FDA oversight." [2] Whether Midi clinicians provide that disclosure consistently is not something the platform has published data on.

Why This Matters for Accreditation

Platforms that prescribe compounded hormones at scale face heightened scrutiny from state boards and the FDA. PCAB accreditation (Pharmacy Compounding Accreditation Board) applies to the compounding pharmacy, not the telehealth platform, but a platform that routes prescriptions to PCAB-accredited pharmacies provides a stronger safety chain. Midi Health has not publicly disclosed which compounding pharmacies it works with or whether those pharmacies hold PCAB accreditation.

Insurance Coverage and Financial Transparency

One feature that distinguishes Midi Health from many direct-to-consumer hormone platforms is its insurance model. The company has signed in-network contracts with several major payers, which means visits are billed as standard outpatient telehealth and subject to the patient's deductible and copay rather than a flat cash membership fee.

What Insurance Covers

A standard Midi Health visit billed to insurance covers the clinical encounter. Laboratory tests ordered during that visit, such as FSH, estradiol, TSH, or a lipid panel, are billed separately to insurance or to the patient. Prescription costs depend on the patient's pharmacy benefit and whether the prescribed product is a generic FDA-approved hormone (typically low cost) or a compounded preparation (typically not covered by insurance and priced at $80 to $200 per month out of pocket).

Cash-Pay Options

For patients without in-network coverage, Midi Health charges a cash-pay visit fee. The specific amount varies by visit type, and the platform has not published a static fee schedule as of this review. Patients should request a Good Faith Estimate under the No Surprises Act before a first paid visit. The CMS No Surprises Act overview is here.

DEA Registration and Controlled Substance Prescribing

Midi Health's clinical focus on menopause means most prescriptions fall outside DEA scheduling. Estrogen and progesterone are not controlled substances. However, some menopause symptoms, particularly anxiety, sleep disruption, and pain, may prompt clinicians to consider medications that are scheduled.

What Midi Health Has Said Publicly

Midi Health's public materials indicate the platform does not prescribe stimulants or opioids. Low-dose benzodiazepines or z-drugs for sleep (Schedule IV) may be prescribed in some clinical contexts depending on clinician judgment and state law. Any clinician prescribing a Schedule III or IV substance must hold an active DEA registration. The DEA's Diversion Control Division maintains a public registrant lookup at deadiversion.usdoj.gov. Patients can verify their clinician's DEA number directly through that tool.

How Midi Health Compares on Key Legitimacy Markers

A structured comparison against common telehealth legitimacy benchmarks helps contextualize the findings above.

LegitScript Status Across Comparable Platforms

Several menopause and HRT telehealth competitors, including Alloy Women's Health and some Hims and Hers properties, do hold LegitScript certification. Midi Health's absence from that list is a verifiable gap. It does not indicate illegal operation, but it does mean the independent audit has not been completed.

BBB vs. URAC vs. NCQA Accreditation

URAC and NCQA are the two most recognized telehealth-specific accreditation bodies in the U.S. URAC's telehealth accreditation program evaluates care coordination, clinical protocols, and quality metrics. NCQA's health innovation accreditation covers similar ground for digital health organizations. As of this review, Midi Health does not publicly claim URAC or NCQA accreditation. That absence is common among early-stage telehealth companies, but patients seeking the highest verification bar should note it.

Clinical Alignment With Published Guidelines

The 2022 NAMS Hormone Therapy Position Statement recommends initiating HRT for symptomatic women under 60 or within 10 years of menopause onset, absent contraindications. [2] The Endocrine Society's 2023 guideline echoes that recommendation and adds that systemic HRT is preferred over compounded preparations when approved options are available. [1] Midi Health's stated clinical approach aligns with this mainstream guidance, which supports confidence in the clinical content even where administrative and accreditation gaps exist.

Red Flags to Watch For, and None Found With Midi Health So Far

No publicly documented FDA warning letters address Midi Health as of July 2025. No DEA actions appear in the public record. No state medical or nursing board has issued a disciplinary order naming Midi Health as an entity. Those absences do not guarantee future compliance, but they are meaningful inputs.

What Would Constitute a Real Red Flag

A real red flag in this context would be: a state board order suspending a clinician for practicing without a license in that state; an FDA warning letter citing misleading drug claims on the Midi Health website; a LegitScript "rogue" designation; or a pattern of BBB complaints alleging prescription fraud or unlicensed prescribing. None of those exist in the current record for Midi Health.

Ongoing Monitoring Recommendation

Patients enrolled with Midi Health should recheck the LegitScript monitor, the FDA warning letters database, and their state nursing board every 12 months, or any time they receive a new prescription from the platform. Telehealth compliance status can change, and no single review captures a permanent state.

A Note on Menopause Telehealth Quality More Broadly

The menopause telehealth market expanded sharply after 2020. The CDC's 2022 Women's Health Report noted that approximately 1.3 million U.S. Women reach menopause annually. A significant fraction never receive any hormone therapy discussion from a clinician, often because primary care visits are too short to address the full symptom burden. Telehealth platforms specifically designed for this population, Midi Health among them, address a real access gap.

That access benefit is real. Forty-four percent of women in a 2021 survey published in Menopause (N=1,480) reported that their primary care physician had not discussed HRT during a menopause-related visit. [3] Midi Health's model directly targets that gap. The legitimacy question is not whether the unmet need is real. It is whether the platform meeting that need does so with adequate regulatory and quality infrastructure.

At this time, the answer is: Midi Health shows clinically appropriate care alignment and no serious regulatory violations, but has not completed the third-party accreditation steps (LegitScript, URAC, NCQA) that would let patients rely on independent verification rather than self-reported claims. Patients should verify their clinician's license before a first visit, confirm that any compounded prescription is going to a PCAB-accredited pharmacy, and request a cost estimate before agreeing to a cash-pay compounded regimen.